Some good news in the fight against the Covid-19 pandemic. A total of 10 Chinese Covid-19 vaccines have been approved to enter clinical trials in China. Some of them are already in the final testing phase (Phase-3). Phase-3 is the last phase vaccines undergo before being made available for the public. According to the CGC (Centers for Disease Control and Prevention):
“The Clinical development is a three-phase process. During Phase I, small groups of people receive the trial vaccine. In Phase II, the clinical study is expanded and vaccine is given to people who have characteristics (such as age and physical health) similar to those for whom the new vaccine is intended. In Phase III, the vaccine is given to thousands of people and tested for efficacy and safety.”
Four Chinese COVID-19 vaccine variations have started international phase-three medical tests, in line with the State Council joint prevention and control mechanism for COVID-19. Some of the phase-three trials are anticipated to finish the primary round of vaccinations in early September, with initial results expected as early as November.
Phase-three medical trials normally involve thousands of human test candidates to verify the safety and effectiveness of the vaccines, that are key to their marketplace approval.
As the epidemic outbreak has now been largely contained in China, all phase-three trials will be carried out overseas, as within China test centers are not ideally prepared.
Two inactivated COVID-19 vaccines developed by the China National Biotec Group (CNBG) were permitted for phase-three medical trials in different countries in the Middle East and South America, where they are tested on more than 30,000 candidates, according to Yang Xiaoming, president of the CNBG.
An inactivated COVID-19 vaccine developed by Sinovac Biotech Co Ltd is undergoing phase-three medical trials in countries in South America and Southeast Asia, according to Yin Weidong, chairman and CEO of Sinovac.
A recombination of a COVID-19 vaccine with the modified adenovirus as the vector is also undergoing phase-three trials.
According to the guiding principle for the medical assessment of COVID-19 vaccines published by the National Medical Products Administration, the vaccine, if successful, need to offer immunity for a minimum of six months, ideally for longer than one year.
An overall of 10 COVID-19 vaccines were permitted to go into medical trials in China. In addition to the above 4 vaccines that have entered phase-three medical trials, the other vaccine options include recombination of protein vaccines, nucleic acid vaccines and vaccines based on modified influenza viruses as vectors.
A recombination of a protein based vaccine jointly developed by the Chinese Academy of Sciences and a bio-pharmaceutical enterprise in Anhui Province is now in its phase-2.
So good news indeed. Now let’s hope that one of the Chinese Covid-19 vaccines, or any vaccine, will finally help to bring an end to the worldwide pandemic and we can go back to what we love the most: Teaching English in China and help finding the best positions for the right candidates to achieve their dreams to live and work in China. Click here to check out our other blog posts in our very own TEFLBlog.